Understand the source comparison
Best Peptides for Dry Eyes: Evidence-Based Comparison
Thymosin Beta-4 Actin sequestration → epithelial migration; aquaporin-5 upregulation → tear production Phase II trials: 27% Schirmer improvement at 28 days; 52% reduction in corneal staining (Bascom Palmer, 2024) Moderate-to-severe aqueous-deficient dry eye; p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Beta-4
- Actin sequestration → epithelial migration; aquaporin-5 upregulation → tear production
- Phase II trials: 27% Schirmer improvement at 28 days; 52% reduction in corneal staining (Bascom Palmer, 2024)
- Moderate-to-severe aqueous-deficient dry eye; post-LASIK neurotrophic keratopathy
- Compounded formulation; RGN-259 in Phase III development
- Strongest clinical evidence base; first peptide likely to reach FDA approval for dry eye indication
- BPC-157
- VEGF upregulation → limbal neovascularization; epithelial healing acceleration
- Preclinical: 40% faster corneal re-epithelialization vs control in alkali burn models (U. Zagreb, 2023)
- Severe dry eye with limbal stem cell deficiency; chemical injury recovery
- Compounded only; no ophthalmic formulation in regulatory pipeline
- Promising for refractory cases but lacks human safety data for ocular route; most evidence from systemic/GI applications
- GHK-Cu
- Copper-SOD pathway → ROS scavenging; MMP modulation → collagen remodeling
- Observational: 31% reduction in meibomian gland dropout markers in rosacea patients (6-month topical use, IOVS 2022)
- Meibomian gland dysfunction; evaporative dry eye; rosacea-associated ocular inflammation
- Compounded; some cosmetic eye serums contain GHK-Cu but at sub-therapeutic concentrations
- Best mechanistic fit for MGD subtype, which comprises 86% of dry eye cases; safety profile well-established in dermatology